Reference Index

(Almirall data on file 039/0272) Almirall Ltd data on file 039/0272

(Azziz 2003) Azziz R. The Evaluation and Management of Hirsutism. Obstet Gynaecol 2003; 101: 995-1007.

(Azziz 2004) Azziz R, Woods, KS, Reyna, R, Key TJ, Knochenhauer ES, Yildiz, BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol & Metab 2004; 89(6): 2745-2749.

(Barth 1993) (Barth 1993) Barth JH, Catalan J, Cherry CA, Day A. Psychological morbidity in women referred for Treatment of hirsutism. J Psychosom Res. 1993 Sep; 37(6): 615- 9.

(Blume 2007) Blume-Peytavi U, Gieler U, Hoffmann R, Lavery S, Shapiro J. Unwanted Facial Hair: Affects, Effects and Solutions. Dermatology 2007; 215(2): 139-146.

(Blume 2008) Blume-Peytavi U & Hahn S. Medical treatment of hirsutism, Dermatologic Therapy, 2008; 21: 329–339.

(Callender 2005) Callender V, Young C. Combination laser and eflornithine HCI 13.9% cream: A first-line therapy for Fitzpatrick type IV-VI patients with excessive facial hair. Poster for SkinMedica 2005.

(Cronin 1998) Cronin L, Guyatt G, Griffith L, Wong E, Azziz R, Futterweit W, Cook D Dunaif A. Development of a Health-Related Quality-of-Life Questionnaire (PCOSQ) for Women with Polycystic Ovary Syndrome (PCOS). J Clin Endocrinol Metab 1998; 83: 1976-1983.

(Hamzavi 2007) Hamzavi I, Tan E, Shapiro J, Lui H. A randomized bilateral vehicle-controlled study of Eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. J Am Acad Dermatol 2007; 57(1): 54-59.

(Hickman 2001) Hickman JG, Huber F, Palmisano M. Human Dermal Safety Studies with Eflornithine HCI 13.9% cream (Vaniqa), a Novel Treatment for excessive facial hair. Curr Med Res Opin 2001; 16(4): 235-244.

(Hoffman 2008) Hoffman R. A 4-month, open-label study evaluating the efficacy of eflornithine 11.5% cream in the treatment of unwanted facial hair in women using TrichoScan®. Eur J Dermatol 2008; 18(1): 65-70.

(Jackson 2007) Jackson J, Caro JJ, Caro G, Garfield F, Huber F, Zhou W, Lin CS, Shander D, Schrode K, and the Eflornithine HCl Study Group. The effect of Eflornithine 13.9% cream on the bother and discomfort due to hirsutism. Int J Derm 2007; 46: 976-981.

(Knochenhauer 1998) Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR and Azziz R. Prevelance of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrin Metab 1998; 83: 3078–3082.

(Legro 2002) Legro RS. Management and Treatment of Hirsutism in the Elderly Woman. Annals of Long-Term Care 2002; 10(11): 41–47.

(Lipton 2006) Lipton M, Sherr L, Elford J, Rustin M, Clayton W. Women living with facial hair: the psychological and behavioral burden. J Psychosom Res 2006; 61: 161–168.

(Malhotra 2001) Malhotra B, Noveck R, Behr D, Palmisano M. Percutaneous Absorption and Pharmacokinetics of Eflornithine HCl13.9% Cream in Women with Unwanted Facial Hair. J Clin Pharmacol 2001; 41: 972–978.

(Rittmaster 1997) Rittmaster RS. Hirsutism. Lancet 1997; 349: 191–195.

(Schrode 2000a) Schrode K, Huber F, Staszak J, Altman DJ, Shander D, Morton J, and the Eflornithine Study Group. Randomized, double-blind vehicle-controlled safety and efficacy evaluation of eflornithine 15% cream in the treatment of women with excessive facial hair. Presented at 58th Annual Meeting of the Academy of Dermatology 2000, 10–15 March, San Francisco, USA, Poster 291.

(Schrode 2000b) Schrode K, Huber F, Staszak J, Altman DJ, and the Eflornithine Study Group. Evaluation of the long-term safety of Eflornithine 15% cream in the treatment of women with excessive facial hair. Presented at the 58th Annual Meeting of the Academy of Dermatology 2000, 10-15 March. San Francisco; USA, Poster 294.

(Shapiro 2005) Shapiro J & Lui H. Treatments for Unwanted Facial Hair. Skin Therapy Letter 2005 Dec-2006 Jan; 10(10): 1-4.

(Smith 2006) Smith SR, Piacquadio DJ, Beger B, Litter C. Eflornithine Cream Combined with Laser Therapy in the Management of Unwanted Facial Hair Growth in Women: A Randomized Trial. Derm Surg 2006; 32: 1237-1243.

(Sonino 1993) Sonino N, Fava GA, Mani E, Belluardo P, Boscaro M. Quality of life of hirsute women. Postgrad Med J 1993; 69: 186-189.

(SPC 2010) Vaniqa® Summary of Product Characteristics, September 2010.

(Trueb 2002) Trueb RM. Causes and management of hypertrichosis. Am J Clin Dermatol 2002; 3(9): 617-27.

(Wolf 2007) Wolf JE Jr, Shander D, Huber F, Jackson J, Lin CS, Mathes BM, Schrode K and the Eflornithine HCl Study Group. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. Int J Dermatol. 2007 Jan; 46(1): 94-98.